Sun Pharma Advanced Research Company Limited
NSE: SPARCMarket Closed • NSE
Day range
52 week range
Sun Pharma Advanced Research Company Limited closed at INR185.60 (-1.14%) on volume 0.84x its 20-day average, trading 35.78% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved -101.2% QoQ
2021-09-21
AGM Announced
Annual General Meeting
2020-09-22
AGM Announced
Annual General Meeting
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Strong Capital Efficiency: ROCE stands at 164.0%
Low Debt Profile: Debt-to-Equity is comfortable at 0.42x
Attractive Valuation: P/E of 3.8x trades below sector historical averages
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| — | Annual General Meeting | Annual General Meeting | — | 21 Sept 2021 |
| — | Annual General Meeting | Annual General Meeting | — | 22 Sept 2020 |
| — | Annual General Meeting | Annual General Meeting | — | 18 Jul 2019 |
| — | Annual General Meeting | Annual General Meeting | — | 19 Jul 2018 |
| — | Annual General Meeting | Annual General Meeting | — | 27 Jul 2017 |
| — | Extraordinary General Meeting | Extraordinary General Meeting | — | 25 May 2017 |
| — | Annual General Meeting | Annual General Meeting | — | 21 Jul 2016 |
| 17 Mar 2016 | Rights issue | Rights 5: 116 At Premium Rs 244/- Per Share | — | 16 Mar 2016 |
| — | Annual General Meeting | Annual General Meeting | — | 23 Jul 2015 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.92 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.48L | 84.75 | 0.32% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.77L | 74.39 | 0.82% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.17L | 183.15 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.15L | 55.26 | 0.26% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.11L | 24.91 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.10L | 100.67 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.05L | 31.20 | 0.99% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products.[1]
IndiaHealthcare
Is Sun Pharma Advanced Research Company Limited Shariah compliant?
Sun Pharma Advanced Research Company Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (9.28%) complies with AAOIFI threshold (≤ 33%).
What is Sun Pharma Advanced Research Company Limited's current valuation relative to peers?
Sun Pharma Advanced Research Company Limited trades at a P/E of 3.8x compared to the sector median of 37.6x, and a Price-to-Book of 4.5x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.42x and a Net Debt to EBITDA ratio of 0.35x. Interest coverage is 47x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 89.9% while net profit growth averaged consistent levels.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-09. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.